Eesti - eesti - Ravimiamet

stada arzneimittel ag - apomorfiin - süste-/infusioonilahus - 10mg 1ml 5ml 25tk; 10mg 1ml 2ml 5tk; 10mg 1ml 5ml 50tk; 10mg 1ml 2ml 25tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - amlodipiin - tablett - 10mg 500tk; 10mg 10tk; 10mg 50tk; 10mg 90tk; 10mg 98tk; 10mg 100tk; 10mg 30tk; 10mg 250tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+amlodipiin - õhukese polümeerikattega tablett - 160mg+5mg 280tk; 160mg+5mg 30tk; 160mg+5mg 56tk; 160mg+5mg 28tk; 160mg+5mg 14tk; 160mg+5mg 90tk

Eesti - eesti - Ravimiamet

ever neuro pharma gmbh - apomorfiin - infusioonilahus - 5mg 1ml 20ml 1tk; 5mg 1ml 20ml 10tk; 5mg 1ml 20ml 30tk; 5mg 1ml 20ml 5tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - apomorfiin - süstelahus pen-süstlis - 10mg 1ml 3ml 5tk; 10mg 1ml 3ml 25tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, maksa - erinevate alimentary seedetrakti ja ainevahetust tooted - ravi ägeda maksa porfüüria (ahp) täiskasvanud ja noorukid vanuses 12 aastat ja vanemad.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Euroopa Liit - eesti - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunosupressandid - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Euroopa Liit - eesti - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprasool - skisofreenia - psühhoeptikumid - skisofreenia säilitusravi täiskasvanud patsientidel, kes stabiliseerusid suu kaudu manustatava aripiprasooliga.

Euroopa Liit - eesti - EMA (European Medicines Agency)

bayer ag - riociguat - hüpertensioon, kopsuvähk - antihüpertensiivsed ravimid kopsuarteri hüpertensioonile - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efektiivsust on näidatud pah elanikkonnale, sh aetiologies idiopaatiline või pärilik pah või pah seotud sidekoe haigus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.